New research, supported by MAGEC—a Phenomics Australia node specialising in in vivo genome engineering and disease modelling—has unravelled how mutations in a gene can lead to an incurable neurodevelopmental disorder that causes abnormal brain development in newborns and infants.
This story was first published at the WEHI website.
Header image: This image shows neurons and their connections to each other in red and yellow, and the cell’s DNA in blue. Credit: Simone Seizova and Shiraz Tyebji, WEHI
The WEHI study is the first to prove that a protein called Trabid helps control neuronal development, and that mutations to this protein can lead to microcephaly – a condition where a baby’s brain is smaller than expected.
It’s hoped the milestone findings will provide a deeper understanding into the protein’s impact on development and may inform new treatments that prevent microcephaly and potentially other neurological disorders.
At a glance
- World-first study shows how mutations in the Trabid protein can cause microcephaly, an incurable brain disorder.
- The research is the first to uncover Trabid’s critical role in neurons, revealing an important role in the functioning of our nervous system. Abnormalities in neuronal development can prevent the brain from developing properly.
- These findings could see Trabid used as a therapeutic target to treat neurodevelopmental disorders in the future.
Microcephaly is a neurodevelopmental condition leading to an underdeveloped brain that adversely affects learning and behaviour.
About 1 in 2,000 babies in Australia are reported to have microcephaly. There currently is no known cure or standard treatment for the disorder.
Neurons are the fundamental building blocks of the nervous system, responsible for transmitting electrical and chemical signals that enable communication between different parts of the body and the brain.
The WEHI-led study is the first to show that Trabid plays a critical role in the behaviour of neurons by ensuring they are guided correctly in the developing brain – ultimately enabling normal brain function and behaviour.
Co-lead author, Professor Grant Dewson, said the findings may aid diagnosis and treatment of neurodevelopmental disorders in the future, with 2.5 million Australians believed to be living with one of these conditions.
“Our understanding into how neurodevelopmental conditions, like microcephaly, develop continues to grow,” Prof Dewson, a Laboratory Head at WEHI, said.
“While previous research has indicated there could be a link between defects in Trabid and microcephaly, our study is the first to provide evidence for the gene’s function in neuronal guidance –filling a vital knowledge gap.”
The study, with first authors Dr Daniel Frank, Dr Maria Bergamasco (now at Charles Perkins institute, University of Sydney), Dr Michael Mlodzianoski, is published in the journal, eLife.
Critical development
In 2015, UK researchers published a study that first suggested a possible connection between the gene encoding Trabid (ZRANB1) and microcephaly, after identifying two children with the brain disorder who had mutations in this gene.
Dr Hoanh Tran, now a group leader at the Peter Doherty Institute for Infection and Immunity, has over 10 years of experience investigating Trabid. Dr Tran leveraged his experience to build on this research by characterising these patient mutations in the lab using pre-clinical models.
“Abnormalities in neuron migration and guidance can lead to neurodevelopmental disorders like microcephaly” Dr Tran said.
“Cells in the developing brain must migrate to the right location. If the address is missed, developmental defects can occur.
“Healthy neurons extend long processes called axons in a directional, ordered manner. In our study, we found the neurons from models with defective Trabid project axons that migrate with a wayward trajectory.
“These significant findings provide an understanding of Trabid/ZRANB1 as a new human microcephaly gene.”
Therapeutic interventions
Currently, microcephaly can sometimes be diagnosed with an ultrasound test during the second or third trimester.
The team hopes that, in future, defects in Trabid, or the proteins that Trabid controls, could help identify babies who are at-risk of developing microcephaly – allowing for potential early interventions.
The research involved collaborations between WEHI’s Ubiquitin Signalling Division, Epigenetics and Development Division, Centre for Dynamic Imaging and Professor Elizabeth Vincan and her team from The Peter Doherty Institute for Infection and Immunity.
The work was supported by the National Health and Medical Research Council, the Bodhi Education Fund, Phenomics Australia, the Australian Government and the Victorian State Government.
With an established track record and reputation for excellence, Phenomics Australia In Vivo Genome Engineering and Disease Modelling team uses techniques such as CRISPR-mediated mutagenesis, classical gene targeting, and transgenesis to create optimal tools for your research delivering a comprehensive service in genome modification. To meet the high demand for this platform, Phenomics Australia offers genome editing services through five nodes across Australia, operating at Monash, ANU, ONJCRI, SAHMRI and PeterMac.
